Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
| Brand name | CINACALCET |
| Generic name | CINACALCET |
| Active ingredient(s) | CINACALCET HYDROCHLORIDE |
| Distributed by / for | Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059 |
| NDC | 69097-411-02 |
| Full product label | Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-411-02 |
| Recalling firm | Cipla USA, Inc. |
| Distribution | Nationwide in the US |
| Quantity | 15,744 bottles |
| Recall initiated | 2025-11-14 |
| Report date | 2025-12-17 |
| Recall completed | — |
| Recall number | D-0225-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗